Business
Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments
Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April STRO-002 Preclinical Data Presented at 2020 AACR Virtual
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April\n STRO-002 Preclinical Data Presented at 2020 AACR Virtual Annual Meeting II in June Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors\n STRO-001 Dose Escalation Ongoing in Phase 1 Clinical Trial for Multiple Myeloma and Lymphoma\n Sutro's Partner Merck KGaA, Unveiled Preclinical Data from the Collaboration's potential First-in-Class Bispecific Antibody-Drug Conjugate at AACR Virtual Annual Meeting II in June\n\n\nSOUTH SAN FRANCISCO, Calif., Aug. 6, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today reported its financial results for the quarter ended June 30, 2020 and its recent business highlights and developments.\n\"Our two proprietary antibody-drug conjugate (ADC) product candidates, STRO-001 and STRO–002, are progressing in Phase 1 clinical trials. We continue to be encouraged by the dose escalation safety and anti-tumor activity data from our Phase 1 clinical trial for STRO-002, including data presented during the AACR Virtual Meeting on April 27, 2020, which demonstrate preliminary evidence of anti-tumor activity, particularly in a heavily pre-treated patient population, along with an emerging safety profile that indicates that the product candidate has been generally well tolerated,\" said Bill Newell, Sutro's Chief Executive Officer. \"Additionally, each of our three current collaborations has yielded a novel oncology product candidate in clinical development or in the late stages of preclinical development, all of which were discovered and developed, and are manufactured, using our proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™. Importantly, even with the ongoing COVID-19 pandemic, Sutro remains committed to the health and safety of both patients receiving our therapies and our employees.\" \nRecent Business Highlights and Developments\nSTRO-002 Clinical Program -- Encouraging STRO-002 Interim Phase 1 Clinical Data from an Ongoing Dose Escalation Study in Ovarian Cancer Presented at the AACR Virtual Meeting in April 2020...